DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as in Phase 2 to treat preeclampsia, cardio renal disease, and fetal growth restriction. The company develops DM300, which is a recombinant human ulinastatin in the preclinical stage for the treatment of inflammatory diseases, such as acute pancreatitis. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota. Show more

301 Carlson Parkway, Minneapolis, MN, 55305, United States

https://www.diamedica.com

Biotechnology

Healthcare

Start AI Chat

Market Cap

364M

52 Wk Range

$5.25 - $10.42

Previous Close

$6.56

Open

$6.56

Volume

189,481

Day Range

$6.49 - $6.89

Enterprise Value

310.2M

Cash

43.5M

Avg Qtr Burn

-8.114M

Insider Ownership

27.83%

Institutional Own.

40.91%

Qtr Updated

06/30/26

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
DM199 (KLK1 protein) Details Heart disease, Ischemic stroke	Phase 2/3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Rinvecalinase Alfa (DM199) (KLK1 Protein) Details Early-Onset Fetal Growth Restriction	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
DM199 (KLK1 protein) Details Chronic inflammatory disorder, Inflammatory disease, Kidney disease, IgA nephropathy, Chronic kidney disease	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Rinvecalinase Alfa (DM199) (KLK1 Protein) Details Early-Onset Preeclampsia	Phase 2 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
DM199 (KLK1 protein) Details Preeclampsia	Phase 2 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.